# Table of Contents

**Chapter 1**  
Introduction and outline of the thesis  9

**Chapter 2**  
Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET  21

*Lung Cancer. 2016 May 31. doi: 10.1016/j.lungcan.2016.05.025*

**Chapter 3**  
Development of $[^{11}\text{C}]$erlotinib Positron Emission Tomography for *in vivo* evaluation of Epidermal Growth Factor Receptor mutational status  67


**Chapter 4**  
Quantitative and Simplified Analysis of $^{11}\text{C}$-Erlotinib Studies  95

*J Nucl Med 2016; 57:861–866*

**Chapter 5**  
Effects of erlotinib therapy on $[^{11}\text{C}]$erlotinib uptake in EGFR mutated, advanced NSCLC  115


**Chapter 6**  
Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy  141

*Personalized Medicine, 2015, 12(2): 63-66*

**Chapter 7**  
Pilot study of $^{89}\text{Zr}$-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer  149

*EJNMMI Research 2014, 4:35*

**Chapter 8**  
Discussion and summary  167

Nederlandstalige samenvatting  177

Dankwoord  189

List of publications  195